This invention was made with no government support. The government has no rights in this invention.
Proteins perform many, if not most, functions in biology, from cellular message signaling to gene transcription. A protein's three-dimensional structure is intimately related to the function of the protein. The three-dimensional structure is often formed by so-called “weak” bonds, such as, but not limited to, hydrogen bonds and van der Waals forces. Via disruption of these weak bonds, proteins often undergo dynamic transitions including folding, unfolding, and conformational changes to perform biological functions in living cells. Beyond the static structure-function relationship, the dynamic relationship between protein conformations and their functions has been extensively studied. Mechanical force interaction and fluctuation of both the amplitude and the vector orientations on proteins can be significant in a living cell, being originated from the biological component movements and interactions, such as, molecular aggregation, molecular partition crowding, hydrodynamic stress, cell osmotic pressure, and cell entropic surface tension.
Disruption of the three-dimensional structure can impact the function of the protein dramatically. For example, proteins can refold improperly after disruption, forming a structure that functions differently or not at all. Clusters of proteins can be disrupted and then refold back to an entangled structure state with unexpected properties. Such entanglements can be found with tau proteins, which are thought to play a role in neurodegenerative diseases such as Alzheimer's or dementia, aggregating into a fibril. In addition, disruption in chromatin or histone proteins can trigger uncontrolled or random changes to gene expression, which can lead to gene translational diseases such as cancer.
Manipulating protein conformations for exploring protein structure-function relationships has shown a great promise. And, although protein conformational changes under pulling force manipulation have been extensively studied, protein conformation changes under a compressive force have not been explored quantitatively. The latter is even more biologically significant and relevant in revealing the protein functions in living cells, associated with protein crowdedness, distribution fluctuations, and cell osmotic stress. There is a need in the art for methods of regulating conformational changes of protein under compressive forces.
Provided herein is a method for preventing or reducing rupture of a protein from a compressive force, the method comprising exposing the protein to a concentration of a cation effective to prevent or reduce rupture of the protein from the compressive force. In certain embodiments, the protein is present in a human cell. In certain embodiments, the protein is a globular protein. In certain embodiments, the the protein is selected from the group consisting of tau, HPPK, nitric oxide synthase (NOS), and calmodulin (CaM).
In certain embodiments, the cation is selected from the group consisting of metallic cations and organic cations. In certain embodiments, the cation comprises Ca2+. In certain embodiments, the cation comprises Mg2+. In certain embodiments, the cation comprises Zn2+. In certain embodiments, the concentration of the cation is a micromolar concentration. In certain embodiments, the concentration of the cation is a millimolar concentration.
In certain embodiments, the compressive force is about 12 pN. In certain embodiments, the compressive force is about 35 pN. In certain embodiments, the compressive force is about 60 pN.
In certain embodiments, the protein is in an aqueous solution. In particular embodiments, the aqueous solution is present in a living cell of a subject. In particular embodiments, the subject is selected from the group consisting of human, mammal, and other animal In particular embodiments, the subject has a neurodegenerative disease or other condition involving protein misfolding, dysfunction, or aggregation.
Further provided is a method of causing a spontaneous protein rupture, the method comprising applying a picoNewton compressive force to a protein to cause the protein to spontaneously rupture. In certain embodiments, the picoNewton compressive force is applied by a tip of an atomic force microscope. In certain embodiments, the applied compressive force is at least 20 pN. In certain embodiments, the applied compressive force is at least 25 pN. In certain embodiments, the applied compressive force is at least 60 pN. In certain embodiments, the applied compressive force is at least 75 pN.
Further provided is an aqueous solution comprising a protein with a rupture threshold exposed to a compressive force in excess of the rupture threshold; and a concentration of a cation; wherein the concentration of the cation is sufficient to prevent rupture of the protein upon exposure to the compressive force in excess of the rupture threshold, and the protein is in a non-ruptured state.
The patent or application file may contain one or more drawings executed in color and/or one or more photographs. Copies of this patent or patent application publication with color drawing(s) and/or photograph(s) will be provided by the U.S. Patent and Trademark Office upon request and payment of the necessary fees.
Throughout this disclosure, various publications, patents, and published patent specifications are referenced by an identifying citation. The disclosures of these publications, patents, and published patent specifications are hereby incorporated by reference into the present disclosure in their entirety to more fully describe the state of the art to which this invention pertains.
A protein under compressive force can act either as a “balloon” or a “cotton ball.” A balloon may rupture under compressive force and a cotton ball only changes shapes but does not rupture. By charge electric field modification, the protein rigidity can be softened to a more flexible form that can diffuse compressive forces by releasing stress to the local environment and through protein shape changes. In accordance with the present disclosure, disruption of a protein's three-dimensional structure can be caused by pico-Newton compressive forces, and this disruption can be stopped by micromolar or millimolar concentrations of cations, such as, but not limited to, Ca2+, Mg2+, or Zn2+. This provides for various avenues for investigation mechanisms and drug treatment, as well as treatments for conditions involving disrupted protein structure.
For example, provided herein are compositions useful for treating, preventing, or ameliorating a neurodegenerative diseases comprising a micromolar or millimolar concentration of a cation, such as Ca2+, Mg2+, Zn2+, or combinations thereof. Such compositions may further include one or more pharmaceutically acceptable carriers, diluents, or adjuvants.
Pharmaceutical compositions of the present disclosure may comprise an effective amount of a cation (an “active” ingredient), and/or additional agents, dissolved or dispersed in a pharmaceutically acceptable carrier. The preparation of a pharmaceutical composition that contains at least one compound or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 2003, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it is understood that preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biological Standards.
A composition disclosed herein may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection. Compositions disclosed herein can be administered intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, intraosseously, periprosthetically, topically, intramuscularly, subcutaneously, mucosally, intraosseosly, periprosthetically, in utero, orally, topically, locally, via inhalation (e.g., aerosol inhalation), by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 2003, incorporated herein by reference).
The actual dosage amount of a composition disclosed herein administered to an animal or human patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. Naturally, the amount of active ingredient(s) in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above.
In certain embodiments, a composition herein and/or additional agent is formulated to be administered via an alimentary route. Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsules, they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
In further embodiments, a composition described herein may be administered via a parenteral route. As used herein, the term “parenteral” includes routes that bypass the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered, for example but not limited to, intravenously, intradermally, intramuscularly, intraarterially, intrathecally, subcutaneous, or intraperitoneally (U.S. Pat. Nos. 6,753,514, 6,613,308, 5,466,468, 5,543,158; 5,641,515, and 5,399,363 are each specifically incorporated herein by reference in their entirety).
Solutions of the compositions disclosed herein as free bases or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Pat. No. 5,466,468, specifically incorporated herein by reference in its entirety). In some cases, the form should be sterile and should be fluid to the extent that easy injectability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (i.e., glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and/or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, such as, but not limited to, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption such as, for example, aluminum monostearate or gelatin.
For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
Sterile injectable solutions are prepared by incorporating the compositions in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized compositions into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, some methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. A powdered composition is combined with a liquid carrier such as, but not limited to, water or a saline solution, with or without a stabilizing agent.
In other embodiments, the compositions may be formulated for administration via various miscellaneous routes, for example, topical (i.e., transdermal) administration, mucosal administration (intranasal, vaginal, etc.), and/or via inhalation.
Pharmaceutical compositions for topical administration may include the compositions formulated for a medicated application such as an ointment, paste, cream, or powder. Ointments include all oleaginous, adsorption, emulsion, and water-soluble based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only. Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones, and luarocapram. Possible bases for compositions for topical application include polyethylene glycol, lanolin, cold cream, and petrolatum, as well as any other suitable absorption, emulsion, or water-soluble ointment base. Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the composition and provide for a homogenous mixture. Transdermal administration of the compositions may also comprise the use of a “patch.” For example, the patch may supply one or more compositions at a predetermined rate and in a continuous manner over a fixed period of time.
In certain embodiments, the compositions may be delivered by eye drops, intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering compositions directly to the lungs via nasal aerosol sprays has been described in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in their entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts and could be employed to deliver the compositions described herein. Likewise, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety), and could be employed to deliver the compositions described herein.
It is further envisioned the compositions disclosed herein may be delivered via an aerosol. The term aerosol refers to a colloidal system of finely divided solid or liquid particles dispersed in a liquefied or pressurized gas propellant. The typical aerosol for inhalation consists of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent. Suitable propellants include hydrocarbons and hydrocarbon ethers. Suitable containers will vary according to the pressure requirements of the propellant. Administration of the aerosol will vary according to subject's age, weight, and the severity and response of the symptoms.
In particular embodiments, the compounds and compositions described herein are useful for treating, preventing, or ameliorating certain neurodegenerative diseases or conditions. Furthermore, the compounds and compositions herein can be used in combination therapies. That is, the compounds and compositions can be administered concurrently with, prior to, or subsequent to one or more other desired therapeutic or medical procedures or drugs. The particular combination of therapies and procedures in the combination regimen will take into account compatibility of the therapies and/or procedures and the desired therapeutic effect to be achieved. Combination therapies include sequential, simultaneous, and separate administration of the active compound in a way that the therapeutic effects of the first administered procedure or drug is not entirely disappeared when the subsequent procedure or drug is administered.
Further provided herein is a method of causing a protein rupture comprising applying a picoNewton compressive force to a protein sufficient to cause the protein to spontaneously rupture.
Further provided herein is a method of studying protein rupture involving the use of a customized atomic force microscope (AFM). The AFM is customized to substantially reduce the signal-to-noise level compared to a conventional AFM, and can be utilized to cause and monitor protein rupture by applying a picoNewton compressive force on a protein.
An atomic force microscope is a useful tool to study enzymatic reactions, the structure of biomolecules, protein-protein interactions, and membrane dipole potential. Force manipulation, mainly using an atomic force microscope (AFM), has been extensively applied on interrogating protein structure and function. Typically, the mechanical force applied by an AFM tip on a protein molecule can be either compressive force or pulling force. Notably, pulling force spectroscopy has provided important knowledge about the mechanical, chemical, and structural properties of protein molecules such as folding/unfolding of biomolecules, peptide-peptide interactions, and molecular interactions. Nevertheless, it is also crucial to analyze the impact of compressive force on proteins in terms of their structures, associated functions, and activities. There are a number of technical approaches to combine single molecule spectroscopy and imaging technique with AFM-correlated microscopy. A combined AFM-TIRF microscopy technique which can probe unfolding dynamics of a small ubiquitin protein along the vertical axis has been developed. A “confocal laser scanning microscope/AFM system” has also been developed where one can simultaneously record the fluorescence spectra of a green fluorescence protein while applying mechanical force on it. Single-molecule optical detection, especially single-molecule fluorescence resonance energy transfer (smFRET), has been widely used to study biomolecules like DNA, RNA, and proteins. It provides detailed information of biomolecules' conformational changes in real time with sub-nanometer resolution. Furthermore, combining smFRET with AFM, an AFM-FRET spectroscopic nanoscope has been demonstrated to be a powerful approach for manipulating and exploring protein structure and functions.
Using a single-molecule AFM-FRET spectroscopic nanoscope, pico-Newton level compressive force was applied on a targeted protein molecule, as described in these examples. Simultaneously, the conformational response of the individual protein was probed by both AFM force spectroscopy and smFRET spectroscopy (
6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is a 158-residue monomer kinase enzyme protein which acts as a catalyst in the pyrophosphorylation reaction that drives the conversion of 6-hydroxymethyl-7,8-dihydropterin (HP) to 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (HPPP) in the presence of ATP leading to the biosynthesis of folate cofactors. AFM was used to apply the compressive force on single protein molecules that are tethered on the glass cover slip surface at a controlled low density for single-molecule measurements. The enzyme HPPK was labeled with Cy3/Cy5 donor acceptor FRET pair on the amino acid residues 88 and 142, respectively (
The structural rupture of a single HPPK protein under compressive force applied by AFM tip was evaluated.
Control experiments show that there are no such force abrupt drop events recorded when the AFM tip approaches the modified surface of the cover glass with either (3-aminopropyl) trimethoxysilane or isobutyltrimethoxysilane with no protein molecules (
To further prove that the force abrupt drop (47-75 pN drop) recorded in a force curve is due to the HPPK molecule sudden structural rupture, besides the simultaneous identification from the correlated recording of FRET trajectory, additional control experiments were performed on a glass surface that does not have a HPPK molecule tethered. All these experiments were done in three different conditions: non-modified bare glass surface, glass surface coated with only —NH2 terminal ((3-aminopropyl) trimethoxysilane), and glass surface coated with only —CH3 terminal (isobutyltrimethoxysilane). All the control experiments were conducted in PBS buffer solution (pH=7.4). The 47-75 pN abrupt force drop seen in the approaching force curves in the correlated measurements were not observed in the approaching force curves recorded in the blank control measurements under all of these three conditions. The results indicate that the pN level force abrupt drop events observed in the approaching curves are only associated with the targeted protein molecules, but not collapse or deconstruction of coated layer molecules. It is also consistent with the finding that the structural rupture under compressive force is a common behavior of protein molecules.
Using the single-molecule AFM-FRET nanoscopic approach to manipulate the protein, detailed force-time trajectories and correlated smFRET-time trajectories were obtained.
To further characterize the HPPK structural rupture events, the Pearson's product-moment correlation coefficient, rF,E, between FRET efficiency and force at the force abrupt drop time was analyzed, representing total correlation at rF,E=1, and no correlation at rF,E=0. Pearson's product-moment correlation coefficient analysis between FRET efficiency E(t) and measured force F(t) (eqn. 1) was used.
Where T is the index of FRET efficiency time trajectory based on 2 ms bin; n is the number of data points within each calculation window (12 data points were used in the calculation (
Similarly, to confirm CaM protein rupture events, the distribution of Pearson's product-moment correlation coefficient between FRET efficiency and the force near the force abrupt drop time was plotted, showing that the Pearson's product-moment correlation coefficient reaches the maximum at the moment of the rupture events. The distribution of the coefficient is narrowly pin-pointed at the rupture event time, whereas the distribution tends to be much broader when t<−0.1 s and t>0.1 s away from the rupture event time.
To evaluate the relation between the compressive threshold force and the tip approaching velocity, the experiment was repeated under different approaching velocities (
A two-state theoretical model, the Bell-Evans theory (eqn. 3), was used to analyze the linear dependence of rupture force with the logarithm of loading rate (
where F(r) is the most probable rupture force; kB, the Boltzmann's constant; T, temperature in Kelvin; Xβ is the distance between the bonded state and the transition state where the activation barrier is located; r, the loading rate; and ko the off-rate constant at zero force. The fitting gives two model parameters, kinetic off rate constant ko=12.2±4.5 s−1 and the distance from the bound to transition state, Xβ=0.34±0.05 nm. Using ko, the barrier height of the transition state (ΔG) was also calculated using the following equation (eqn. 4), where h is the Planck's constant. ΔG of HPPK protein rupture is 27.0±9.8 kBT.
To demonstrate the protein rupture behavior generally exists in other proteins, similar AFM force manipulations were carried out on individual calmodulin (CaM) proteins, and similar spontaneous ruptures of CaM under the pN force manipulation were observed.
To evaluate the relation between threshold force of protein rupture and AFM tip approaching velocity, i.e., the apparent loading rates (ALR), the experiments were repeated under four different ALRs.
The threshold force required for a single protein HPPK to rupture increases from 47 pN to 75 pN as the approaching velocity increases from 200 nm/s to 2000 nm/s, and the threshold force increases linearly along with log (ALR) (
The real rupture induction length of a protein under compressive force was estimated. The length reflects the actual structural change experienced by the protein molecule at the process of the compressive force loading to the threshold value on an examined protein molecule. The force trajectories were further analyzed based on the following experimental facts: (1) the distance traveled by the AFM piezoelectric scanner exceeds the distance traveled by the AFM tip apex due to bending of the cantilever upon force loading, and the latter can be accounted by using the average cantilever force constant of 30 pN/nm; and (2) the aqueous solvation layer or the hydration shell around a protein is at least 1˜2 nm. Therefore, the apparent height of tethered protein molecule on the glass surface is at least few nm higher than what the crystal structure shows just considering the contribution of hydration shell. This attribution is further supported by the results of the force curve measurements. Notably, in all the force curves (
The AFM piezoelectric displacement distribution (
The experiments for CaM protein were repeated under five different ALRs.
The findings involving calmodulin were further explored. Calmodulin is a ubiquitous calcium binding protein with 148 residues (16.7 KDa) that plays crucial roles in its Ca2+-ligated activated form in the transduction of Ca2+ signals. It performs this role by binding to several targets inside the cell including ion channels and a large number of enzymes and proteins.
The crystal structure of Ca2+-ligated CaM has a very distinct dumbbell shape, where two approximately symmetrical globular C- and N-terminal domains are separated by a 27 residue long α-helical linker (
When Ca2+ ions are removed from the EF hand motifs of calmodulin, it transforms to a more bound conformational state Apo-CaM from its prominent dumbbell shape (
In the experiment of compressive force manipulation on both Apo- and Ca2+-ligated CaM, a modified AFM apparatus with an ultra-soft AFM tip was used to apply compressive force on a single protein molecule tethered to a glass coverslip through covalent bonding between the linker molecule and amino group of the protein, and its response was studied. It was found that Apo-CaM molecules undergo an abrupt spontaneous rupture at ˜70 pN (see supplemental information below) of compressive force.
The same experiment was carried out on Ca2+-ligated CaM.
Although the crystal structure of Ca2+-ligated calmodulin shows the central helix in α-helix form, the NMR structure conclusively shows this linker is nonhelical and very flexible around its middle point, from residue K77 to S81. The anisotropy observed for the motion of the two lobes was much smaller, which indicates that in Ca2+-ligated calmodulin, tumbling of both N terminal and C terminal lobes are mutually independent. This flexible central helix structure model is further supported by the structure of the CaM molecule complexed with target peptides, where these target peptides induce collapse of the elongated dumbbell structure forming a globular structure around the helical target peptide. In the presence of Ca2+ ions, this extended flexibility gives the CaM protein the conformational freedom where it can release the tension and avoid an abrupt rupture under compressive force. In other words, in the presence of Ca2+, a CaM molecule behaves more like a non-rigid sphere where it can easily change its shape redistributing the loading force applied by the AFM tip. As a result, the molecule does not go through a structural rupture under a compressive force.
On the other hand, in absence of Ca2+, the central helix of Apo-CaM is significantly less flexible which forbids both the domains to come together and bind to the peptide. The significantly larger degree of anisotropy in rotational diffusion observed for Apo-calmodulin relative to Ca2+-ligated calmodulin further shows that the linker is more rigid in the Apo state compared to the Ca2+ activated state. The Apo-CaM is in a more bounded state, which contributes to its structural rigidity whereas Ca2+-ligated calmodulin is in an open state. When the force reaches a threshold value of ˜70 pN, the CaM can no longer hold the force, and the molecule gets ruptured spontaneously and abruptly.
Protein rupture under compressive force is a spontaneous process driven by a threshold amount of force. As the AFM force loading is very slow at 1.5 nm/ms, temperature around the protein remains constant and the rupture dynamics follow a typical energy profile with an energy crossing barrier that includes the complex nature of dynamic bond breaking, intramolecular interaction dynamics, and liquid friction force. The inhomogeneous nature of the protein rupture indicates the inhomogeneous local environment constituted by different orientations of the protein molecules along with different electric, hydrophilic, and hydrophobic force fields of the single protein molecules, solvent molecules, and the linker molecules on the cover glass surface. Structural rigidity attributed from interdomain interactions, hydrogen bonds, and solvent dynamics is very important to study protein structure-function relationship associated with protein-protein, protein-peptide interactions, and enzymatic reactions.
The structural flexibility and rigidity of the calmodulin molecule play a very important role in protein function associated with binding other proteins and peptides. Numerous attempts have been made over the years to address the flexibility of calmodulin in the presence and absence of Ca2+ using NMR and other techniques, but it is still hotly debated due to the absence of direct evidence. It is significant that the structural rigidity of a protein molecule can be probed by using a compressive force. It further proves that the compressive force is equally sensitive like a pulling force to sense such a miniscule amount of structural change in terms of flexibility and compactness. Furthermore, spontaneous single protein rupture of the bound Ca2+-deactivated form was also observed under compressive force, which may be a plausible mechanism leading to protein mis-folding and entangled aggregation.
The tau protein was also investigated. Tau is an intrinsically disordered protein (IDP) that plays a very important role in stabilizing axonal microtubules in the central nervous system. Tau 441 has two inserts at the N-terminal end, a proline-rich region, four repeats (R1, R2, R3, and R4), and a short C-terminal tail. In pathogenic form, tau loses its affinity towards the microtubule, and these four repeat domains fold together forming a β-sheet structure and aggregates as fibrillary tau. The role of tau protein in neurodegeneration is still unclear, but it is already known that tau mutation inducing tau aggregation is closely associated with tauopathies. It is believed that tau protein aggregation is transmittable in neurons in a prion-like manner.
Tau is a highly water-soluble protein and positively charged in physiological condition. NMR structure study indicates the structural diversity of tau protein in the solution and complicated network of transient long-range interactions. Due to the absence of a fixed tertiary structure, tau protein is believed to exist as an IDP in solution. Both circular dichroism measurements and electron paramagnetic resonance have shown a higher degree of mobility of the tau protein structure.
Both the molecular basis of early aggregation events and the mechanism by which tau aggregation causes neuronal dysfunction are still unclear. For aggregation, the IDP needs to undergo through conformational changes to form the “pro-aggregate”. It is observed that tau repeat domains K18 and K19 can aggregate much faster than the full-length tau. Tau mutation in frontotemporal dementia FTDP-17 is known for increasing β-sheet propensity making the structure more prone to aggregation.
Single molecule study has also shown evidence that tau protein is not completely lacking structural motifs. A Forster resonance, energy transfer study showed a much shorter intramolecular distance than a random coil model. A single molecular fluorescence polarization anisotropy study has shown that tau protein under solution exists in two conformations. These two long-lived conformations adopted by tau protein vary in terms of compactness.
In these examples, spontaneous tau protein rupture under compressive force manipulation using an atomic force microscope (AFM) is demonstrated. It was found that tau protein undergoes a spontaneous rupture when the compressive force reaches a threshold value depending on the tip approaching speed. It was also found that, in the presence of Mg2+ ions, tau protein does not show such rupture events, whereas the rupture event remains in the presence of monovalent cations like K+. This gives the indication of the presence of two forms of tau protein under different ionic environment. Under K+environment tau protein exists as a relatively rigid protein structure which is more prone to collapse under compressive force build up. With the addition of Mg2+ ions, the protein relaxes to a more flexible conformation that does not show any rupture. In addition, it was also investigated whether this kind of spontaneous and simultaneous rupture of multiple proteins under close proximity can develop an entangled protein third state, a fusion state, and can be a plausible mechanism for protein aggregation.
Compactness, rigidity, and force withholding are proportionally closely related concepts: they go high and low proportionally and monotonically. Compactness is more about the envelope of the protein outer sphere volume; rigidity is more about the protein inner structure collective stiffness and stability of the structure under thermal fluctuation; force withholding is about the force holding inside the protein structure, mostly reflected by stress, which is a direct consequence or association of the protein structure rigidity and compactness.
This spontaneous protein rupture at the threshold compressive force reveals a unique hidden property associated with the rigidity of the tau protein structure in solution. Protein structure constituted with intermolecular hydrogen bonding, interdomain interactions, friction force with the solvent molecule and interdomain frictions can form structural rigidity which can withstand pN amount of compressive force applied by the AFM tip apex. When the compressive force reaches a threshold value the protein can no longer hold the force and gets ruptured. Though tau protein is intrinsically disordered protein in solution, it exists in different conformational states. These conformational states can be either long lived or short lived, and vary in terms of compactness. Ensemble average measurement gives the average picture of disordered protein structures in an averaged timescale, but the real picture of single molecular conformational fluctuation can be much more complex and different. Protein molecules can exist in a more rigid state for a time being, enabling the protein structure to withstand pN compressive force. Not only that, but increased hydrophobicity by the linker and the trimethoxy silane molecules can also induce the protein to form a globular structure. This increased molecular rigidity allows the AFM tip to load a pN scale of compressive force on the protein. Once the force reaches the threshold value, it causes multiple hydrogen bond rupture, and frictional force relaxation under intermolecular and protein-solvent interactions.
This protein spontaneous rupture under compressive force is a complex event which includes inhomogeneous local factors like a hydrophilic hydrophobic force field of the protein molecules and the surrounding. This inhomogeneous nature of the protein rupture gives a broad distribution of the threshold force. The AFM force loading process is a relatively slow process compared to the protein conformational fluctuation time, which ensures that the rupture process follows an isothermal dynamic with a free-energy downhill kinetics. The scale of the rupture force at pN can be biologically available in living cells under the influence of thermal fluctuation, molecular crowding, and anisotropic force field. The anisotropic nature of force fluctuation inside the cells can generate pN compressive force that is capable of triggering such protein ruptures. A ruptured protein molecule can stay in a metastable or sub stable state and can refold back to its original folded state. Should more than one protein ruptured at the same time in a proximity, the ruptured proteins may fold into an entangled state, which may be an early event of protein aggregation. Nevertheless, it is highly remarkable that there may be a link between the protein rupture under compressive force and the protein aggregation.
To further characterize the rupture threshold force distribution and mean rupture force, the experiment was repeated under the different approaching speed of the AFM tip.
To further investigate that whether the rupture events are closely related to the local environment, it was found that the protein rupture behaviors are highly sensitive to the charge of the cations in solution. As Mg2+ ions were added, no rupture event was found (
Protein rupture under compressive force can be irreversibly consequential inside the cell under protein crowding. A ruptured protein can stay in a metastable state, can refold back to its original state, or can stay in a different conformational state. Under molecular crowding, the compressive force fluctuation can trigger a rare event involving multiple protein ruptures, and the simultaneously ruptured protein cluster can fold up into an entangled aggregation. To demonstrate this mechanism, an AFM pulling experiment followed by compressive force loading was conducted, inducing a pair of protein ruptures. The AFM tip was covered with a monolayer of tau protein with a significantly short linker. A force matrix experiment was performed on a coverglass surface that was covered with tethered tau protein in a single molecular low concentration, where the AFM tip was approached by some points apart from each other by a certain distance, and both the approaching curve and the pulling curve was recorded. The experiment was performed under a buffer solution (pH 7.4) with 2000 nm/s approaching velocity. The pulling rupture force was measured and plotted against the displacement.
There is a significant difference in the nature of the protein rupture dynamics under pulling force and compressive force. Protein rupture under pulling force is a force driven process in every step, whereas the protein rupture in the compressive experimental force application described herein is a spontaneous process initiated by a threshold force to put the protein matrix at the starting point of the spontaneous process. As the force loading is slow at 0.2 nm/ms, the compressive force loading is an isothermal process, and the protein remains at equilibrium with a constant temperature surrounding. The intrinsically isothermal dynamics follow the activation crossing barrier process under the liquid friction force and molecular intra-protein interaction network matrix. The protein rupture process under the threshold compressive force is a complex process involving binding and unbinding, dissociation and association, multiple coordinate force vectors, relaxation, and accumulation. Furthermore, it also involves complex factors, such as stochastic noncovalent interactions, conformational deformation, tension distribution within the targeted protein, surface adsorption, and desorption between the AFM tip and the protein molecule. Nevertheless, the real experimental local environment creates an energy landscape for the ruptured state of the protein, and the potential energy well is deeper than the metastable or far-from-equilibrium protein state under the threshold compressive force. The local environment is constituted by the protein's electric, hydrophilic, and hydrophobic force fields associated with different orientations of the protein on the cover glass surface, as well as the hydrocarbon modified surface of the coverglass. The local solvation layers are formed by the water and buffer electrolyte solution. Nevertheless, there is an inhomogeneous local environment that provides inhomogeneous protein rupture event energy landscapes, and in turn, gives inhomogeneous protein rupture energetics and dynamics.
It is remarkable that the structural rupture can be observed as a response of a globular protein under a compressive force directly applied upon it. This protein function and behavior are demonstrated and identified quantitatively in the correlated single-molecule AFM force manipulation and fluorescence imaging spectroscopy experiments described herein, and the observations cannot be achieved by conventional AFM imaging and force manipulation alone. Furthermore, the rupture threshold force is relatively weak, and the threshold compressive force loading energy is 4-30 kBT, depending on different proteins. Moreover, the protein rupture behavior is also highly sensitive to the local environment as the rupture events are free energy driven and spontaneously occur when the compressive force reaches the threshold. The related biological impact on protein functions and protein dynamics can be highly extensive and profound, since the force fluctuations are capable of providing the threshold compressive force in living cells to trigger transient protein ruptures that may be followed by protein misfolding and entangled aggregations closely related to human neuronal degenerative diseases, such as brain chronic traumatic encephalopathy and neurofibrillary tangles.
Protein structure spontaneous rupture was observed under mechanical compressive force directly applied by the AFM-FRET single-molecule nanoscopic approach. The rupture of protein molecule under compressive force is an abrupt and spontaneous process, and the threshold force is rather weak, ranging from 12 pN to 75 pN, which is a biologically relevant force amplitude in living cells with significant biological consequences.
In addition, AFM compressive force was utilized to manipulate and characterize both calcium activated and deactivated forms of calmodulin. Upon loading of compressive force on a single Apo-CaM molecule, an abrupt and spontaneous rupture of the protein was observed, which is an unexplored property of the protein. On the other hand, no such events were observed in the case of the Ca2+-ligated form. The Ca2+-ligated form is more flexible, which makes it unable to hold force. This protein property is highly significant in protein functions in living cells, as the thermal fluctuation local force fluctuations may provide such a pN force and trigger a protein structure collapse or a multiple protein collapse simultaneously at the same location, a catastrophic unfolding event, that may be associated with protein dysfunction, aggregation, and misfolding.
Tau protein rupture was observed under pN of compressive force, which indicates the presence of some rigid conformational states of an intrinsically disordered protein. This rigidity may be the possible reason for tau aggregation. It was also found that structural rigidity of a protein is closely related to the electrochemical environment. In the presence of Mg2+, tau protein exists in a more relaxed and flexible form than in a K+ environment. This indicates an imbalance of certain ions can impact the rigidity of a protein, which can trigger the protein aggregation.
It is very important to have a molecular understanding of the earliest steps of the protein aggregation. Here an understanding of the protein aggregation process under influence of compressive force in a crowded environment is described. Simultaneously ruptured proteins in crowding can either refold back to their individual native states or refold into an entangled state as both pathways are energetically accessible. (
The examples herein show that by changing the concentration of cation, one can prevent or reduce the amount or frequency of protein rupture when that protein is subjected to a compressive force. The experimental conditions described above indicate that proteins in living cells are also subjected to compressive forces and, likewise, that specific cation concentrations can prevent or reduce ruptures. Accordingly, the present disclosure is useful in evaluating new drug candidates or as a treatment itself.
Ions have a huge variety of roles in cells. Ions that can be used in accordance with the present disclosure include ions involved in electrical communication (Na+, K+, Ca2+), as cofactors in dictating protein function with entire classes of metalloproteins (constituting, by some estimates, at least ¼ of all proteins), in processes ranging from photosynthesis to human respiration (Mn2+, Mg2+, Fe2+), as a stimulus for signaling and muscle action (Ca2+), and as the basis for setting up transmembrane potentials that are then used to power key processes such as ATP synthesis (H+, Na+). In addition, organic ions can be used in some embodiments.
Concentrations of ions used in accordance with the present disclosure can be within physiological ranges. Physiological ranges usually means, but is not limited to, concentrations in the millimolar range. One skilled in the art will understand that this range will depend, for example, on the ion itself, the type of cell or fluid in which the ion is present, and the physiological state of that cell (e.g., dormant or excited neuros will have different concentrations of certain cations). These examples are one of many factors known to those skilled in the art involved in determining what is a physiological concentration of ion. Many outside references address this complicated topic, such as, but not limited to, “Cell Physiology Source Book: Essentials of Membrane Biophysics,” 4th Edition, ed. Nicholas Speralakis, 2012, Academic Press, which is hereby incorporated by reference for all purposes.
The cover glass (Gold Seal) was first cleaned and silanized with a mixture of (3-aminopropyl) trimethoxysilane and isobutyltrimethoxysilane with a ratio of 1:10000 dissolved in DMSO (10% v/v) for 12 hours, and then incubated in 10 nM dimethyl suberimidate in 50 mM PBS (pH 8.0) for 4 h. After washing by water and methanol, the glass slide was incubated in 10 nM HPPK solutions (PBS, pH 7.4) for 4 h. The possibility of two protein molecules locating underneath the AFM tip or in the same laser focus spot of around 300 nm diameters is almost zero. Cy3-Cy5 labeled HPPK molecules were tethered randomly on a cover glass surface and then incubated in PBS buffer (pH=7.4) in a homemade chamber immobilized on top of the microscope. To decrease photobleaching, added 0.8% D-glucose, 1 mg/mL glucose oxidase, 0.04 mg/mL catalase, and about 1 mM Trolox were added in the buffer as an oxygen scavenger. To make sure that only one specific single-molecule HPPK molecule was probed at a time, the HPPK molecules were tethered to the glass surface with diluted concentration by controlling the ratio of the mixture of (3-aminopropyl) trimethoxysilane and isobutyltrimethoxysilane, and 1:10000 is the ratio that was used to ensure that the possibility of two or more HPPK molecules within an area defined by the diffraction limit is virtually zero.
After making the AFM tip coaxially aligned with the excitation laser, the x-y position of the AFM tip was fixed, and moving the sample stage alone can allow for switching different single molecules and implementing further measurements. Due to instrumental drifting, further routine adjustments were undertaken, but they were relatively minor compared to the initial alignment. The whole process for the correlated AFM-FRET alignment is shown in
The home-built experimental setup was composed primarily of an inverted optical microscope (Axiovert-200, Zeiss) and an AFM scanning module (PicoSPM, Agilent) in an over-under configuration. The excitation laser (532 nm) beam was reflected by a dichroic beam splitter (z532rdc, Chroma Technology) and focused by a high-numerical-aperture objective (1.3 NA, 100X, Zeiss) on the sample surface at a diffraction limited spot of about 300 nm in diameter. To obtain a single-molecule FRET image and photon-counting time trajectories, the emission signal was split using a dichroic beam splitter (640dcxr) into two-color beams centered at 570 nm and 670 nm representing the emissions of the Cy3 and Cy5 donor-acceptor dye pair, respectively. The two-channel signals were collected by a pair of Si avalanche photodiode single photon counting modules (SPCM-AQR-16, Perkin Elmer Optoelectronics) for detecting the single-molecule fluorescence. It was possible to obtain a fluorescence image (ranging from 1 μm×1 μm to 100 μm×100 μm, typically 10 μm×10 μm) by continuously raster-scanning the sample over the laser focus with a piezoelectric scanning stage (Physik Instruments Inc., Germany) at any scanning speed (typically ranging from 1 ms/pixel to 30 ms/pixel), with each image being normally 100 pixels×100 pixels. Typically, fluorescence intensities of the FRET donor (Cy3) and acceptor (Cy5) were collected for several hundred seconds by a two-channel Picoharp 300 (PicoQuant) time-correlated single photon counting (TCSPC) system.
A manual two-axis x-y mechanical positioning stage (Zeiss) and a two-axis close loop x-y 100 μm piezoelectric-scanner stage (Physik Instruments) were mounted directly on the optical microscope. The two-axis close loop x-y piezoelectric-scanner stage was controlled by a computer with a raster scan software, by which the sample was able to be scanned over laser in two-dimension (2D) to provide images and identify positions of dye-labeled single-molecule proteins within the laser focal spot. The two-axis x-y mechanical positioning stage was used to support the close-loop AFM scanning module (PicoSPM, Agilent). With that, the AFM tip was moved in 2D on top of the x-y piezoelectric-scanning stage independently, and the AFM tip was positioned to co-axial with the laser beam from the microscope objective. An AFM scanner was used to scan topographic images or manipulate single molecules by force. A home-built fluid cell was put on top of the sample (a transparent glass cover-slide) to keep the sample in buffer solution. To avoid the FRET signal from being interfered by AFM laser, the AFM scanning module was modified by an infrared superluminescent diode (SLD) at 950 nm to replace the conventional 650 nm laser source. A shortpass filter E835sp (OMEGA Optical) was put in front of the detectors to block the AFM infrared photons and a longpass filter HQ5451p (Chroma Technology) was put to block 532 excitation laser: M: Mirror, Dichroic beam splitter 1: z532rdc (Chroma Technology), reflecting 532 nm excitation laser beam and transmitting fluorescence. Dichroic beam splitter 2: 640dcxr (Chroma Technology), splitting the emission signal into two color beams centered at 570 nm and 670 nm representing Cy3 and Cy5 emissions. APD 1: Si avalanche photodiode single photon counting modules (SPCM-AQR-16, Perkin Elmer Optoelectronics) for detecting the single-molecule fluorescence Cy5. APD 2: Si avalanche photodiode single photon counting modules (SPCM-AQR-16, Perkin Elmer Optoelectronics) for detecting the single-molecule fluorescence Cy3. Filter 1: HQ5451p (Chroma Technology), blocking 532 nm excitation laser beam. Filter 2: E835sp (OMEGA Optical), blocking AFM infrared 950 nm beam.
Lining up the optical focal point and AFM tip is the first and critical step for a typical operation of the AFM-FRET nanoscopy. First, the x-y two-axis mechanical positioning stage was moved to roughly align the AFM tip with the laser beam focal point by observing the reflection pattern of the AFM tip; a symmetric light reflection pattern can be observed from the microscope objective. It indicates that the coaxial position is achieved within a few micrometers.
To co-axially align the AFM tip with the laser beam center of Gaussian distribution of the laser focus, the AFM tip is scanned across the area of the laser beam that has been aligned, and one of the APD signals is sent to the AFM controller through a gated photon counter SR400 (Stanford Instruments, CA) as shown in
While the AFM tip is repeatedly pushed down and pulled up, multiple force spectroscopic data and FRET trajectories are collected simultaneously, and they are recorded in the same temporal axis. The FRET efficiency was calculated by the donor acceptor intensity using the formula EFRET=IA/(IA+ID), where IA is the fluorescence intensity of the acceptor and ID is the fluorescence intensity of the donor. As the AFM tip was moving down and closer to the laser focal point, the detected photon counts in both donor and acceptor channels rose due to a previously reported micro-mirror reflection effect, resulting in a higher signal collection efficiency. Typically, the micro-mirror effect appears or disappears at 150 nm above the sample surface.
FRET intensity trajectories correlate with compressive force curve measurements.
The Pearson's product-moment correlation coefficient analysis was used between FRET efficiency E(t) and measured force F(t) (eqn. 1):
where T is the index of FRET efficiency time trajectory based on 2 ms bin; n is the number of data points within each calculation window (12 data points were used in the calculation (
A control experiment for the signal-to-noise ratio of the fluorescence photon detection by the correlated single-molecule AFM-FRET nanoscope was performed. After the AFM tip was positioned coaxially with the excitation laser focus, the sample was raster scanned in 10 ms/pixel, and the fluorescence intensity data were collected during the scanning (
The loading energy was calculated using Eloading=J F(l)dl. l is the compressive force loading distance, and F(l) is the loading force curve. The force constant of AFM cantilever=30 pN/nm, and the average rupture threshold force is 47 pN under 200 nm/s force loading velocity. In the calculation, the force being linearly increased during loading process was considered, which gives F(l) =Fthreshold. Under the above approximation, the distribution of calculated threshold compressive force loading energy is plotted for HPPK and CaM, given kBT=4.114 pN.nm. Most of the rupture events are triggered by loading energy around 30 kBT for HPPK and 4-8 kBT for CaM protein.
Immobilized CaM was incubated in an EGTA-containing buffer (20 mM HEPES, 2 mM EGTA, pH 8) at room temperature for 15 minutes and then treated with PBS buffer (pH 7.4) for five minutes. This process was repeated for four times to remove the Ca2+ ion from CaM, inducing CaM to change to the Apo-CaM conformation.
Typical compressive force curves were recorded under different conditions.
A force vs force loading distance curve is shown in
In accordance with the provisions of the patent statutes, the present invention has been described in what is considered to represent its preferred embodiments. However, it should be noted that the invention can be practiced otherwise than as specifically illustrated and described without departing from its spirit or scope.
Certain embodiments of the compositions and methods disclosed herein are defined in the above examples. It should be understood that these examples, while indicating particular embodiments of the invention, are given by way of illustration only. From the above discussion and these examples, one skilled in the art can ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the compositions and methods described herein to various usages and conditions. Various changes may be made and equivalents may be substituted for elements thereof without departing from the essential scope of the disclosure. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the disclosure without departing from the essential scope thereof.
This application claims priority to United States Provisional Application No. 62/787,886 filed under 35 U.S.C. § 111(b) on Jan. 3, 2019, the disclosure of which is incorporated herein by reference in its entirety for all purposes.
Number | Date | Country | |
---|---|---|---|
62787886 | Jan 2019 | US |